Nachrichten zur Vertex Pharmaceuticals Inc. Aktie

Prediction: Vertex Pharmaceuticals Will Be 1 of the Best Biotech Stocks to Own Over the Next 5 Years

The drugmaker hasnt disappointed long-term shareholders.…

Vertex Pharmaceuticals Aktie: Pove-Zulassung und Pipeline könnten neue Impulse liefern

RBC Capital hebt das Kursziel für Vertex Pharmaceuticals auf 600 USD und setzt auf starken Cashflow sowie neue Zulassungs- und…

Vertex Pharmaceuticals Aktie: Hoffnung auf Medikamentenzulassung beflügelt die Fantasie!

BMO Capital erhöht Kursziel…

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report.…

Vertex Pharmaceuticals Gets 96% of Product Sales From Treatments for 1 Disease. Heres Why Thats About to Change.

Vertex is expanding beyond its cystic fibrosis franchise.…

AbbVie vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie generates $17.8 billion in annual free cash flow but faces patent cliffs, while Vertex boasts a 33% net margin…

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know

Vertex Pharmaceuticals (VRTX) closed at $514.7 in the latest trading session, marking a +2.54% move from the prior day.…

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

Vertex Pharmaceuticals (VRTX) reached $508.75 at the closing of the latest trading day, reflecting a +2.06% change compared to its…

Moderna vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just…

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $510.08, marking a +1.36% move from the previous day.…

Vertex Pharmaceuticals Aktie: Starkes Quartal voraus? Neue Kursfantasie durch RBC!

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von RBC Capital Markets:Die Analysten vom Investmenthaus RBC Capital Markets belassen die Aktie von Vertex…

Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.…

Axsome Therapeutics vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?

Vertex dominates cystic fibrosis with expanding disease coverage and a pipeline entering new therapeutic areas. Axsome is building a commercial…

Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Heres What You Need to Know

Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.…

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Heres Why

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $508.34, signifying a -1.55% move from its prior days close.…

ServiceNow Aktie: JPMorgan sieht neuen Wachstumsmotor - Klares Kaufsignal

Bad Marienberg (www.aktiencheck.de) - Bei Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol: VX1, NASDAQ-Symbol: VRTX) kommt neue Bewegung in…

Vertex Pharmaceuticals Aktie (Monatschart): Doppelter Ausbruch - doppelt konstruktiv? Chartanalyse

Düsseldorf (www.aktiencheck.de) - Vertex Pharmaceuticals-Chartanalyse von HSBC Trinkaus & Burkhardt:Die Analysten von HSBC Trinkaus & Burkhardt nehmen die Aktie von…

Vertex Pharmaceuticals Rally Has a New Engine -- and Wall Street Thinks the Best Is Still Ahead

Dont bet against Vertex Pharmaceuticals in cystic fibrosis.…

Diese 5 Gründe sprechen für einen Kauf von Vertex Pharmaceuticals

Vertex Pharmaceuticals (VRTX) finde ich aus fünf konkreten Gründen nun spannend für neue Long-Manöver. Der SPDR S&P Biotech ETF (XBI) hat…

Vertex Pharmaceuticals Just Hit an All-Time High. Heres Why the Biotech Stock Could Soar Even More

The drugmaker should significantly mitigate its most important risk as it develops new products.…

Vertex Pharmaceuticals Aktie: Studienflop beim Rivalen - Analyst sieht neue Chancen!

Charlotte (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von BofA Securities:Die Analysten von BofA Securities raten die Aktie von Vertex Pharmaceuticals Inc. (ISIN:…

Vertex Pharmaceuticals Q2 2026 Zahlen: Umsatz über 3,3 Mrd. USD - Prognose steigt

Bad Marienberg (www.aktiencheck.de) - Vertex Pharmaceuticals Inc. (ISIN: US92532F1003, WKN: 882807, Ticker-Symbol: VX1, NASDAQ-Symbol: VRTX) liefert für das zweite Quartal…

Vertex Pharmaceuticals Incorporated 2026 Q2 - Results - Earnings Call Presentation

…

Vertex Pharmaceuticals (VRTX) Q2 Earnings Lag Estimates

Vertex (VRTX) delivered earnings and revenue surprises of -1.25% and +3.32%, respectively, for the quarter ended June 2026. Do the…

Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?

Vertex (VRTX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its upcoming…

Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $472.57, marking a -1.96% move from the previous day.…

Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $480.5, denoting a -1.06% move from the…

Vertex Pharmaceuticals Aktie: Übernahme von Crinetics sorgt für Fantasie

Charlotte (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse der Bank of America (BofA):BofA habe das Kursziel für die Aktie von Vertex Pharmaceuticals Inc.…

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

Additional blockbuster drugs may be on the horizon.…

Vertex Pharmaceuticals Aktie: Kursziel steigt auf 570 USD - Biotech-Sektor vor starkem Quartal?

Toronto (www.aktiencheck.de) - Vertex Pharmaceuticals-Aktienanalyse von RBC Capital Markets:Die Analysten von RBC Capital haben das Kursziel für die Aktie von…

Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note

Vertex Pharmaceuticals (VRTX) closed at $522.25 in the latest trading session, marking a -1.39% move from the prior day.…

SpaceX Joins Nasdaq 100; Crinetics Pharmaceuticals Soars on Buyout | Stock Movers

On this episode of Stock Movers:- Fiserv (FISV) is climbing as the Wall Street Journal reports big banks including JPMorgan…

Vertex kauft Crinetics für 10 Mrd. USD! Zwei neue Umsatzbringer und FDA-Zulassungen geben Aufwind!

Milliarden-Zukauf: Vertex übernimmt Crinetics Pharmaceuticals für 10,0 Mrd. USD, um das Portfolio außerhalb der Mukoviszidose strategisch zu erweitern Pipeline-Expansion:…

Vertex Pharmaceuticals: Wichtige Diversifikation sorgt für Big Picture-Breakout

Vertex (VRTX) habe ich aufgrund der hohen Abhängigkeit vom Franchise zur Behandlung von zystischer Fibrose (CF) und der sich anbahnenden…

Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?

Dyne pursues rare disease breakthroughs while Vertex leverages blockbuster profits for pipeline expansion, how do their risk profiles and financials…

Why the Market Dipped But Vertex Pharmaceuticals (VRTX) Gained Today

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $491.34, denoting a +2.32% move from the…

Vertex Pharmaceuticals (VRTX) Rises Higher Than Market: Key Facts

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $444.41, denoting a +2% move from the…

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $435.76, signifying a -2.25% move from its prior days close.…

Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?

A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026…

Halozyme (HALO) Q1 2026 Earnings Transcript

Image source: The Motley Fool.DateMonday, May 11, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Helen TorleyInterim Chief Financial…

Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Beat Estimates

Vertex (VRTX) delivered earnings and revenue surprises of +5.76% and +0.19%, respectively, for the quarter ended March 2026. Do the…

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Heres Why

Vertex Pharmaceuticals (VRTX) reached $430.5 at the closing of the latest trading day, reflecting a -1.06% change compared to its…

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

The latest trading day saw Vertex Pharmaceuticals (VRTX) settling at $441.2, representing a +1.27% change from its previous close.…

Vertex Pharmaceuticals (VRTX) Stock Slides as Market Rises: Facts to Know Before You Trade

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $435.65, indicating a -1.37% shift from the previous trading…

Is Vertex Pharmaceuticals Empire in Trouble?

It might not be too late to invest in this company.…

Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know

Vertex Pharmaceuticals (VRTX) reached $436.16 at the closing of the latest trading day, reflecting a -2.38% change compared to its…

Vertex Pharmaceuticals (VRTX) Stock Drops Despite Market Gains: Important Facts to Note

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $438.75, moving 1.9% from the previous trading session.…

Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Heres Why

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $454.97, signifying a +1.42% move from its prior days close.…

Absci (ABSI) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DATETuesday, March 24, 2026 at 4:30 p.m. ETCALL PARTICIPANTSFounder and Chief Executive Officer — Sean McClainChief…

MaxCyte (MXCT) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DATETuesday, March 24, 2026 at 4:30 p.m. ETCall participantsChief Executive Officer — Maher MasoudChief Financial Officer…